Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

(2018) Asha Nayak-Kapoor et al.   Journal for ImmunoTherapy of Cancer

Targeting TDO in cancer immunotherapy

(2017) Cheng-Peng Yu et al.   MEDICAL ONCOLOGY

Postnatal Changes in Humerus Cortical Bone Thickness Reflect the Development of Metabolic Bone Disease in Preterm Infants

(2016) Shuko Tokuriki et al.   DISEASE MARKERS

Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis

(2016) Ya-Ling Hsu et al.   Oncotarget

A phase I study of indoximod in patients with advanced malignancies

(2016) Hatem H. Soliman et al.   Oncotarget

Metabolic communication in tumors: a new layer of immunoregulation for immune evasion

(2016) Ping-Chih Ho et al.   Journal for ImmunoTherapy of Cancer

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer

(2015) Nicholas C. D'Amato et al.   CANCER RESEARCH

Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration and invasion of human hepatocellular carcinoma

(2015) Haojie Jin et al.   Scientific Reports

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan

(2015) N. van Baren et al.   Cancer Immunology Research

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

(2015) Nicolas van Baren et al.   Frontiers in Immunology

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

(2011) L Ferdinande et al.   BRITISH JOURNAL OF CANCER

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

(2010) Soranobu Ninomiya et al.   ANNALS OF HEMATOLOGY

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy

(2010) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Immune escape as a fundamental trait of cancer: focus on IDO

(2008) G C Prendergast   ONCOGENE